UBS Group’s Interpace Biosciences, Inc. Common Stock IDXG Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-2,946
| Closed | -$9K | – | 9954 |
|
|
2020
Q4 | $9K | Sell |
2,946
-526
| -15% | -$1.73K | ﹤0.01% | 7599 |
|
|
2020
Q3 | $11K | Buy |
+3,472
| New | +$15.7K | ﹤0.01% | 6823 |
|
|
2020
Q2 | – | Sell |
-1,390
| Closed | -$7K | – | 8760 |
|
|
2020
Q1 | $7K | Sell |
1,390
-437
| -24% | -$3.16K | ﹤0.01% | 7196 |
|
|
2019
Q4 | $91K | Buy |
+1,827
| New | +$11.8K | ﹤0.01% | 6060 |
|
|
2019
Q3 | – | Sell |
-100
| Closed | -$1K | – | 8488 |
|
|
2019
Q2 | $1K | Sell |
100
-618
| -86% | -$4.52K | ﹤0.01% | 7795 |
|
|
2019
Q1 | $6K | Buy |
718
+23
| +3% | +$216 | ﹤0.01% | 7126 |
|
|
2018
Q4 | $6K | Buy |
+695
| New | +$8.34K | ﹤0.01% | 7515 |
|
|
2018
Q3 | – | Sell |
-721
| Closed | -$6K | – | 8461 |
|
|
2018
Q2 | $6K | Buy |
+721
| New | +$6.39K | ﹤0.01% | 7436 |
|
|
2017
Q3 | – | Sell |
-867
| Closed | -$8K | – | 8165 |
|
|
2017
Q2 | $8K | Buy |
867
+746
| +617% | +$14.6K | ﹤0.01% | 6945 |
|
|
2017
Q1 | $3K | Sell |
121
-48
| -28% | -$1.72K | ﹤0.01% | 7232 |
|
|
2016
Q4 | $7K | Buy |
+169
| New | +$5.39K | ﹤0.01% | 7118 |
|
|
2016
Q3 | – | Sell |
-6
| Closed | – | – | 8103 |
|
|
2016
Q2 | $0 | Sell |
6
-24
| -80% | -$903 | ﹤0.01% | 8116 |
|
|
2016
Q1 | $1K | Buy |
+30
| New | +$803 | ﹤0.01% | 7500 |
|
|
2015
Q4 | – | Sell |
-2
| Closed | – | – | 8695 |
|
|
2015
Q3 | $0 | Buy |
+2
| New | +$394 | ﹤0.01% | 8790 |
|
|
2015
Q2 | – | Sell |
-36
| Closed | -$5K | – | 9014 |
|
|
2015
Q1 | $5K | Buy |
+36
| New | +$5.89K | ﹤0.01% | 8138 |
|
Other funds holding IDXG
UBS Group's IDXG Position: Q1 2021 in Review
UBS Group sold out of Interpace Biosciences, Inc. Common Stock (IDXG) in Q1 2021, closing a stake of 2,946 shares — an estimated $9K sold.
UBS Group first reported a position in IDXG in Q1 2015 and held it in 15 quarters. The position peaked at $91K in Q4 2019. 3 funds tracked by Wall St. Rank hold IDXG as of Q1 2021.
- UBS Group reported no remaining Interpace Biosciences, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
- UBS Group sold 2,946 Interpace Biosciences, Inc. Common Stock shares in Q1 2021, an estimated $9K.
- UBS Group first reported a position in Interpace Biosciences, Inc. Common Stock in Q1 2015 and held it in 15 quarters.
- UBS Group's Interpace Biosciences, Inc. Common Stock position peaked at $91K in Q4 2019.
- 3 funds tracked by Wall St. Rank held Interpace Biosciences, Inc. Common Stock as of Q1 2021.
Based on UBS Group's 13F filing for Q1 2021, filed 12 May 2021.